These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 34079050)

  • 1. Systemic GLP-1R agonist treatment reverses mouse glial and neurovascular cell transcriptomic aging signatures in a genome-wide manner.
    Li Z; Chen X; Vong JSL; Zhao L; Huang J; Yan LYC; Ip B; Wing YK; Lai HM; Mok VCT; Ko H
    Commun Biol; 2021 Jun; 4(1):656. PubMed ID: 34079050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternative role of glucagon-like Peptide-1 receptor agonists in neurodegenerative diseases.
    Chen SD; Chuang YC; Lin TK; Yang JL
    Eur J Pharmacol; 2023 Jan; 938():175439. PubMed ID: 36470445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of Glucagon-Like Peptide-1 Receptor Promotes Neuroprotection in Experimental Autoimmune Encephalomyelitis by Reducing Neuroinflammatory Responses.
    Lee CH; Jeon SJ; Cho KS; Moon E; Sapkota A; Jun HS; Ryu JH; Choi JW
    Mol Neurobiol; 2018 Apr; 55(4):3007-3020. PubMed ID: 28456941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The glucagon-like peptide-1 receptor agonist, exendin-4, reduces sexual interaction behaviors in a brain site-specific manner in sexually naïve male mice.
    Vestlund J; Jerlhag E
    Horm Behav; 2020 Aug; 124():104778. PubMed ID: 32450068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acylation of the Incretin Peptide Exendin-4 Directly Impacts Glucagon-Like Peptide-1 Receptor Signaling and Trafficking.
    Lucey M; Ashik T; Marzook A; Wang Y; Goulding J; Oishi A; Broichhagen J; Hodson DJ; Minnion J; Elani Y; Jockers R; Briddon SJ; Bloom SR; Tomas A; Jones B
    Mol Pharmacol; 2021 Oct; 100(4):319-334. PubMed ID: 34315812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuronal cell cycle reentry events in the aging brain are more prevalent in neurodegeneration and lead to cellular senescence.
    Wu D; Sun JK; Chow KH
    PLoS Biol; 2024 Apr; 22(4):e3002559. PubMed ID: 38652714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologically reversible zonation-dependent endothelial cell transcriptomic changes with neurodegenerative disease associations in the aged brain.
    Zhao L; Li Z; Vong JSL; Chen X; Lai HM; Yan LYC; Huang J; Sy SKH; Tian X; Huang Y; Chan HYE; So HC; Ng WL; Tang Y; Lin WJ; Mok VCT; Ko H
    Nat Commun; 2020 Sep; 11(1):4413. PubMed ID: 32887883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of glucagon-like peptide-1 receptor-targeted imaging probe with in vivo glucagon-like peptide-1 receptor agonist glucose-lowering effects.
    Murakami T; Fujimoto H; Fujita N; Hamamatsu K; Yabe D; Inagaki N
    J Diabetes Investig; 2020 Nov; 11(6):1448-1456. PubMed ID: 32323451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GLP-1R activation ameliorated novel-object recognition memory dysfunction via regulating hippocampal AMPK/NF-κB pathway in neuropathic pain mice.
    Zhang LQ; Zhang W; Li T; Yang T; Yuan X; Zhou Y; Zou Q; Yang H; Gao F; Tian Y; Mei W; Tian XB
    Neurobiol Learn Mem; 2021 Jul; 182():107463. PubMed ID: 34015440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of glucagon-like peptide-1 receptor in microglia attenuates neuroinflammation-induced glial scarring via rescuing Arf and Rho GAP adapter protein 3 expressions after nerve injury.
    Qian Z; Chen H; Xia M; Chang J; Li X; Ye S; Wu S; Jiang S; Bao J; Wang B; Kong R; Zhang S; Zheng S; Cao X; Hong X
    Int J Biol Sci; 2022; 18(4):1328-1346. PubMed ID: 35280691
    [No Abstract]   [Full Text] [Related]  

  • 11. Glucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for Parkinson's disease.
    Glotfelty EJ; Olson L; Karlsson TE; Li Y; Greig NH
    Expert Opin Investig Drugs; 2020 Jun; 29(6):595-602. PubMed ID: 32412796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oleoylethanolamide modulates glucagon-like peptide-1 receptor agonist signaling and enhances exendin-4-mediated weight loss in obese mice.
    Brown JD; McAnally D; Ayala JE; Burmeister MA; Morfa C; Smith L; Ayala JE
    Am J Physiol Regul Integr Comp Physiol; 2018 Oct; 315(4):R595-R608. PubMed ID: 29949410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anorectic and aversive effects of GLP-1 receptor agonism are mediated by brainstem cholecystokinin neurons, and modulated by GIP receptor activation.
    Costa A; Ai M; Nunn N; Culotta I; Hunter J; Boudjadja MB; Valencia-Torres L; Aviello G; Hodson DJ; Snider BM; Coskun T; Emmerson PJ; Luckman SM; D'Agostino G
    Mol Metab; 2022 Jan; 55():101407. PubMed ID: 34844019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of efficacy- versus affinity-driven agonism with biased GLP-1R ligands P5 and exendin-F1.
    Marzook A; Chen S; Pickford P; Lucey M; Wang Y; Corrêa IR; Broichhagen J; Hodson DJ; Salem V; Rutter GA; Tan TM; Bloom SR; Tomas A; Jones B
    Biochem Pharmacol; 2021 Aug; 190():114656. PubMed ID: 34129856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exenatide mitigated diet-induced vascular aging and atherosclerotic plaque growth in ApoE-deficient mice under chronic stress.
    Yang G; Lei Y; Inoue A; Piao L; Hu L; Jiang H; Sasaki T; Wu H; Xu W; Yu C; Zhao G; Ogasawara S; Okumura K; Kuzuya M; Cheng XW
    Atherosclerosis; 2017 Sep; 264():1-10. PubMed ID: 28734203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic administration of Glucagon-like peptide-1 receptor agonists improves trabecular bone mass and architecture in ovariectomised mice.
    Pereira M; Jeyabalan J; Jørgensen CS; Hopkinson M; Al-Jazzar A; Roux JP; Chavassieux P; Orriss IR; Cleasby ME; Chenu C
    Bone; 2015 Dec; 81():459-467. PubMed ID: 26314515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microglial Activation of GLP-1R Signaling in Neuropathic Pain Promotes Gene Expression Adaption Involved in Inflammatory Responses.
    Ma L; Ju P; Wang W; Wei J; Wang W; Zhao M; Ahmad KA; Wang Y; Chen J
    Neural Plast; 2021; 2021():9923537. PubMed ID: 34512747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases.
    Diz-Chaves Y; Mastoor Z; Spuch C; González-Matías LC; Mallo F
    Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36076972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A GLP-1:CCK fusion peptide harnesses the synergistic effects on metabolism of CCK-1 and GLP-1 receptor agonism in mice.
    Hornigold DC; Roth E; Howard V; Will S; Oldham S; Coghlan MP; Blouet C; Trevaskis JL
    Appetite; 2018 Aug; 127():334-340. PubMed ID: 29782892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topical Administration of GLP-1 Receptor Agonists Prevents Retinal Neurodegeneration in Experimental Diabetes.
    Hernández C; Bogdanov P; Corraliza L; García-Ramírez M; Solà-Adell C; Arranz JA; Arroba AI; Valverde AM; Simó R
    Diabetes; 2016 Jan; 65(1):172-87. PubMed ID: 26384381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.